Alpha 2.0
Login Register
» Authors » Heather Poad

Heather Poad

Explore the profile of Heather Poad including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 6
Citations 68
Followers 0
Related Specialties
Oncology
General Medicine
Public Health
Top 10 Co-Authors
Sunjay Jain
Maureen Twiddy
Mark Johnson
Phillip Koenig
Louise Goodwin
Matt Simms
Lorna Wheaton
Sam Khan
Sylwia Bujkiewicz
Mohantha Dooldeniya
Published In
BMJ Open
J Clin Oncol
BMC Cancer
Cancers (Basel)
Thorax
Affiliations
Soon will be listed here.
Recent Articles
1.
Individual participant data from digital sources informed and improved precision in the evaluation of predictive biomarkers in Bayesian network meta-analysis
Umemneku-Chikere C, Wheaton L, Poad H, Ray D, Andrade I, Khan S, et al.
J Clin Epidemiol . 2023 Nov; 164():96-103. PMID: 37918640
Objectives: We aimed to develop a network meta-analytic model for the evaluation of treatment effectiveness within predictive biomarker subgroups, by combining evidence from individual participant data (IPD) from digital sources...
2.
The Validity of Surrogate Endpoints in Sub Groups of Metastatic Colorectal Cancer Patients Defined by Treatment Class and KRAS Status
Poad H, Khan S, Wheaton L, Thomas A, Sweeting M, Bujkiewicz S
Cancers (Basel) . 2022 Nov; 14(21). PMID: 36358810
Findings from the literature suggest that the validity of surrogate endpoints in metastatic colorectal cancer (mCRC) may depend on a treatments' mechanism of action. We explore this and the impact...
3.
Radical Cystectomy Against Intravesical BCG for High-Risk High-Grade Nonmuscle Invasive Bladder Cancer: Results From the Randomized Controlled BRAVO-Feasibility Study
Catto J, Gordon K, Collinson M, Poad H, Twiddy M, Johnson M, et al.
J Clin Oncol . 2020 Dec; 39(3):202-214. PMID: 33332191
Purpose: High-grade nonmuscle invasive bladder cancer (HRNMIBC) is a heterogeneous disease. Treatments include intravesical maintenance (mBCG) and radical cystectomy (RC). We wanted to understand whether a randomized trial comparing these...
4.
Randomised, double-blind, multicentre, mixed-methods, dose-escalation feasibility trial of mirtazapine for better treatment of severe breathlessness in advanced lung disease (BETTER-B feasibility)
Higginson I, Wilcock A, Johnson M, Bajwah S, Lovell N, Yi D, et al.
Thorax . 2020 Jan; 75(2):176-179. PMID: 31915308
New treatments are required for severe breathlessness in advanced disease. We conducted a randomised feasibility trial of mirtazapine over 28 days in adults with a modified medical research council breathlessness...
5.
PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma
Buckley H, Collinson F, Ainsworth G, Poad H, Flanagan L, Katona E, et al.
BMC Cancer . 2019 Nov; 19(1):1102. PMID: 31727024
Background: The combination of nivolumab, a programmed death-1 (PD-1) targeted monoclonal antibody, with the cytotoxic T-lymphocyte antigen-4 (CTLA-4) targeted antibody, ipilimumab, represents a new standard of care in the first-line...
6.
Radical cystectomy (bladder removal) against intravesical BCG immunotherapy for high-risk non-muscle invasive bladder cancer (BRAVO): a protocol for a randomised controlled feasibility study
Oughton J, Poad H, Twiddy M, Collinson M, Hiley V, Gordon K, et al.
BMJ Open . 2017 Aug; 7(8):e017913. PMID: 28801444
Introduction: High-risk non-muscle invasive bladder cancer (HRNMIBC) is a heterogeneous disease that can be difficult to predict. While around 25% of cancers progress to invasion and metastases, the remaining majority...